What is the official website of AbbVie ?

The official website of AbbVie is http://www.abbvie.com.

What is AbbVie's cybersecurity risk score?

AbbVie has an AI-generated cybersecurity risk score of 827 out of 1000, indicating a Good security posture according to Rankiteo's assessment.

How many security incidents has AbbVie experienced?

According to Rankiteo, AbbVie currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has AbbVie been affected by any supply chain cyber incidents ?

According to Rankiteo, AbbVie has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does AbbVie have SOC 2 Type 1 certification ?

According to Rankiteo, AbbVie is not certified under SOC 2 Type 1.

Does AbbVie have SOC 2 Type 2 certification ?

According to Rankiteo, AbbVie does not hold a SOC 2 Type 2 certification.

Does AbbVie comply with GDPR ?

According to Rankiteo, AbbVie is not listed as GDPR compliant.

Does AbbVie have PCI DSS certification ?

According to Rankiteo, AbbVie does not currently maintain PCI DSS compliance.

Does AbbVie comply with HIPAA ?

According to Rankiteo, AbbVie is not compliant with HIPAA regulations.

Does AbbVie have ISO 27001 certification ?

According to Rankiteo,AbbVie is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does AbbVie operate in ?

AbbVie operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does AbbVie have ?

AbbVie employs approximately 61,106 people worldwide.

Does AbbVie own any subsidiaries ?

AbbVie presently has no subsidiaries across any sectors.

How many LinkedIn followers does AbbVie have ?

AbbVie's official LinkedIn profile has approximately 2,051,823 followers.

What is the NAICS classification code for AbbVie ?

AbbVie is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does AbbVie have a Crunchbase profile ?

Yes, AbbVie has an official profile on Crunchbase, which can be accessed here: https://www.crunchbase.com/organization/abbvie.

Does AbbVie have a LinkedIn profile ?

Yes, AbbVie maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/abbvie.

How many cybersecurity incidents has AbbVie experienced ?

As of August 2, 2026, Rankiteo reports that AbbVie has experienced 2 cybersecurity incidents.

How many peer or competitor companies does AbbVie have ?

AbbVie has an estimated 5,720 peer or competitor companies worldwide.

What types of cybersecurity incidents has AbbVie faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Vulnerability and Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

AbbVie

Boost Score +25 with badge (5 left)

827

/1000

Good

852

/1000

Very Good

AbbVie Vendor Cyber Rating & Cyber Score

abbvie.com

cb in

Add Your Compliance Badge

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

AbbVie A.I CyberSecurity Scoring

Scoring History

AbbVie

AbbVie CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

AbbVie

Vulnerability

100

4/2026

EGAABB177565877...

AbbVie

Breach

100

6/2023

ABB0473723

Loading…

A.I.

AbbVie Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for AbbVie

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

AbbVie has 34.64% fewer incidents than the average of same-industry companies with at least one recorded incident.

Incidents vs All-Companies Average (This Year)

AbbVie has 2.91% fewer incidents than the average of all companies with at least one recorded incident.

Incident Types AbbVie vs Pharmaceutical Manufacturing Industry Avg (This Year)

AbbVie reported 1 incidents this year: 0 cyber attacks, 0 ransomware, 1 vulnerabilities, 0 data breaches, compared to industry peers with at least 1 incident.

Incident History - AbbVie (X = Date, Y = Severity)

Loading…

SUBSIDIARY

AbbVie Subsidiaries

AbbVie

Pharmaceutical Manufacturing

Website: http://www.abbvie.com

Company Size: 10,001+ employees

Allergan Aesthetics, an AbbVie CompanyPharmaceutical Manufacturing

Allergan Medical InstitutePharmaceutical Manufacturing

BOTOX® Cosmetic (onabotulinumtoxinA)Pharmaceutical Manufacturing

Allergan Aesthetics Plastic and Regenerative Medicine PortfolioMedical Equipment Manufacturing

Natrelle Breast ImplantsPharmaceutical Manufacturing

AbbVie | OncologyPharmaceutical Manufacturing

AbbVie | DeutschlandPharmaceutical Manufacturing

AbbVie | UKPharmaceutical Manufacturing

AbbVieEyetoEyePharmaceutical Manufacturing

AbbVie Contract ManufacturingPharmaceutical Manufacturing

AbbVie | VirologyPharmaceutical Manufacturing

Loading…

AbbVie Similar Companies

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Novartis

cb novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Loading…

NEWS

AbbVie CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

June 30, 2026 01:19 PM

US House Committee Opens Investigation Into Merck, AbbVie China Drug Trials

US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health...

Read Article

June 24, 2026 07:00 AM

AbbVie Stock And 2 Cash Flow Picks Worth A Closer Look

With global growth signals sending mixed messages and central banks taking a cautious approach on interest rates, many investors are looking...

Read Article

February 20, 2026 08:00 AM

AbbVie Inc. SEC 10-K Report

AbbVie Inc., a global biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of...

Read Article

January 13, 2026 08:00 AM

Recon: AbbVie strikes pricing pact with the White House; FDA seeks removal of suicide warnings from weight-loss drugs

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. In Focus: US. Pazdur warns that politics,...

Read Article

December 24, 2024 08:00 AM

Action likely against AbbVie executive who signed self-declaration

Pharma cos and docs say medical conferences have declined since March after UCPMP was notified.

Read Article

August 12, 2024 07:00 AM

QARA Professionals Question a Future with Cybersecurity Issues, US Litigation, and the EU AI Act

At a private event held amid the fallout from the CrowdStrike incident, cybersecurity issues took a front seat, with the consequences of the...

Read Article

July 12, 2024 07:00 AM

Enterprise Risk Mitigation: New ERP Platform Focuses on Cybersecurity and System Validation

The security of Enterprise Resource Planning (ERP) systems has emerged as a critical issue for businesses globally.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-18556

SUMMARY

Authentication bypass using an alternate path or channel vulnerability in N-able N-central allows Authentication Bypass. This issue affects N-central: through 2026.1.

Published

Date2026-08-01

Updated

Date2026-08-01

RISK INFORMATION (Score: )

cvss4

Base Score: 8.2

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:N/PR:N/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://uptime.n-able.com/

CVE-2026-55735

SUMMARY

Improper Verification of Cryptographic Signature in ueberauth guardian allows an unauthenticated attacker to revoke a victim's session with a forged token. Guardian.revoke/3 in lib/guardian.ex decodes the supplied token with peek/1, which performs no signature verification (it only base64-decodes the JWT header and payload). The resulting unverified claims are forwarded directly to the configured token module's revoke callback and the implementation's on_revoke callback, a state-mutating sink. The sibling operations refresh/2 and exchange/4 both call decode_and_verify first, so the signature is checked before anything acts on the claims; revoke/3 is the only state-mutating path that acts on claims without verifying the signature. An attacker who knows or guesses a victim's identifying claim values (jti, sub) can forge a JWT carrying those claims, sign it with an arbitrary key, and submit it to any endpoint that funnels a caller-supplied token into Guardian.revoke/3 (the standard logout / session-revocation pattern). When the token module mutates state keyed by the claims (whitelist deletion or blacklist insertion, for example a GuardianDb-style store), the victim's legitimate session is evicted. This is an unauthenticated session-revocation denial of service; the attacker never needs the signing secret. This issue affects guardian: from 1.0.0 before 2.4.1.

Published

Date2026-08-01

Updated

Date2026-08-01

RISK INFORMATION (Score: )

cvss4

Base Score: 8.2

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-55734

SUMMARY

Allocation of Resources Without Limits or Throttling vulnerability in ueberauth guardian (Guardian.Permissions module) allows a denial of service via BEAM atom-table exhaustion. This vulnerability is associated with program file lib/guardian/permissions.ex and program routines 'Elixir.Guardian.Permissions':encode_permissions!/1, 'Elixir.Guardian.Permissions':encode_permissions_into_claims!/2, 'Elixir.Guardian.Permissions':do_encode_permissions!/2. The Guardian.Permissions mixin installs a public encode_permissions!/1 function on every module that does use Guardian.Permissions. For each key of the supplied map, encode_permissions!/1 calls String.to_atom(to_string(k)) before any validation runs. The integer-value clause of do_encode_permissions!/2 then short-circuits straight to encoding without validating the key against the configured permission set, so a key with an integer value is interned as a fresh atom with no exception raised. Atoms are never garbage collected and the BEAM atom table is a fixed-size resource (default roughly 1,048,576 entries), so each unique attacker-chosen key permanently consumes one slot. An attacker who can influence a permission map that reaches encode_permissions!/1 (for example a permissions map read from a request body and passed into token issuance via encode_permissions_into_claims!/2) can mint an unbounded number of atoms and exhaust the atom table, crashing the entire BEAM node and every service running on it. The sibling decode_permissions/1 is not affected because it skips keys absent from the configured permission set. This issue affects guardian: from 2.0.0 before 2.4.1.

Published

Date2026-08-01

Updated

Date2026-08-01

RISK INFORMATION (Score: )

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:P/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-55733

SUMMARY

Allocation of Resources Without Limits or Throttling in ueberauth guardian allows denial of service via unbounded atom creation from attacker-controlled binary input. Guardian.Permissions.AtomEncoding encodes permission scopes by passing arbitrary binaries to String.to_atom/1. When encode/3 in lib/guardian/permissions/atom_encoding.ex is called with a list, each binary entry is handled by the encode_value/3 binary clause, which calls String.to_atom(value) with no allow-list check. The perm_set argument (the application's small, finite set of legitimate permission names) is discarded, so any external string flows straight into atom creation. This encoder is selected with use Guardian.Permissions, encoding: Guardian.Permissions.AtomEncoding and reached through the imported encode/3 entry point. String.to_atom/1 creates a brand-new atom for every previously unseen binary, atoms are never garbage collected, and the BEAM atom table is fixed at roughly 1,048,576 entries by default. An application that funnels attacker-influenced permission scopes (from a request body, a JWT claim, or other external input) into encode/3 therefore mints one permanent atom per distinct value. A modest stream of varied, unauthenticated input permanently consumes the atom table and crashes the BEAM node with system_limit, taking down every application running on it. The default encoder is Guardian.Permissions.BitwiseEncoding, which is not affected. This issue affects guardian: from 2.0.0 before 2.4.1.

Published

Date2026-08-01

Updated

Date2026-08-01

RISK INFORMATION (Score: )

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:P/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-54894

SUMMARY

Allocation of Resources Without Limits or Throttling in ueberauth guardian allows denial of service via unbounded atom creation from attacker-influenced binary input. Guardian.Plug.Keys derives connection and session namespace keys by passing arbitrary binaries to String.to_atom/1. base_key/1 in lib/guardian/plug/keys.ex converts any binary into the atom :"guardian_<input>", and the derived helpers claims_key/1, resource_key/1, and token_key/1 create a second atom on top of that. key_from_other/1 likewise converts a regex-captured binary through String.to_atom/1. The public specs advertise String.t() as a valid argument, so passing a string is documented usage, and higher-level entry points such as Guardian.Plug.current_token(conn, key: key) thread the caller-supplied key straight into these functions. String.to_atom/1 creates a brand-new atom for every previously unseen binary, atoms are never garbage collected, and the BEAM atom table is fixed at roughly 1,048,576 entries by default. An application that routes attacker-influenced data (a tenant identifier, header, or other request input) into a Guardian key therefore mints one permanent atom per distinct value. A modest stream of varied, unauthenticated input permanently consumes the atom table and crashes the BEAM node, taking down every application running on it. This issue affects guardian: from 0.1.0 before 2.4.1.

Published

Date2026-08-01

Updated

Date2026-08-01

RISK INFORMATION (Score: )

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:P/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…